i) Generic Products

We deliver economical, high-value-added generic drugs underpinned by reliable information provision capabilities.

In June 2021, the Cabinet of Japan stated that generics would be required to represent at least 80% of all drugs dispensed nationwide by FY2023. It also emphasized that generic drugs must be consistently reliable in terms of quality and that supplies must be stable. The Ministry of Health, Labour and Welfare has indicated that, in pursuit of this goal, it will promote the use of generics.

The Nippon Chemiphar Group is applying its integrated capabilities to the development, manufacture, and marketing of new drugs and generics. Regarding the latter, we are pursuing the development of those generics that meet the needs of patients and healthcare professionals. At the same time, we are redoubling our efforts to maintain product quality and ensure stable supplies.

In addition, we are using the experience and expertise we accumulated through the sale of new drugs to provide and collect information regarding the proper use of pharmaceutical drugs while conducting promotional activities targeting medical professionals, in part through events such as research conferences.

ii) Proprietary Products and New Drugs

We aim to add fresh dimensions to our distinctive proprietary products, and develop groundbreaking new drugs.

Nippon Chemiphar categorizes new drugs that it has developed, as well as new drugs and long-listed drugs inlicensed from other companies, as “proprietary products and new drugs.”

Among its proprietary products are three formulations that the Company developed in-house: alkalization therapeutic drug Uralyt-U, analgesic and anti-inflammatory drug Soleton, and hypertension therapeutic drug Calvan.

Included among the new and long-listed drugs we have in-licensed from other companies are new oral intestinal cleansing agent PICOPREP (manufacturing and sales rights acquired in February 2019) and macrolide antibiotic agent Klaricid (exclusive sales launched in July 2020; manufacturing and sales rights acquired in April 2021).We expect these to strengthen our product portfolio and anticipate utilizing them to generate synergies that will help expand our generics business.

At the same time, we are continuing to aggressively pursue drug discovery themes with the potential to result in groundbreaking new drugs. Currently, these efforts are focused on our development pipeline, where we are cultivating new treatments with support from public funding.

From treatment to prevention.

Nippon Chemiphar provides measuring equipment and reagents used to fight allergies and lifestyle-related diseases. In 2020, we began selling DropScreen™, a groundbreaking new product that enables quick allergy screenings to be carried out using minimal blood samples. In the future, we plan to roll out the product in Europe and Southeast Asia.

Expanding benefits.

The Group handles a diverse array of healthcare products, including nutrients, health foods, cosmetics, and various types of creams, classified as quasi-drugs because they contain a certain concentration of particular active ingredients.

Amid the rising needs surrounding consumer self-medication, we are leveraging trustworthiness and the development expertise we have gained as a pharmaceutical product manufacturer to make a difference in people’s lives and provide a high level of added value.